BIOMAT Database Logo BIOMAT Database Logo

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. 1988

J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Investigational Drug Branch, National Cancer Institute, Bethesda, Maryland 20892.

UI MeSH Term Description Entries
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D010746 Phosphonoacetic Acid A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. Phosphonoacetate,Disodium Phosphonoacetate,Fosfonet Sodium,Phosphonacetic Acid,Phosphonoacetate, Disodium
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001224 Aspartic Acid One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. (+-)-Aspartic Acid,(R,S)-Aspartic Acid,Ammonium Aspartate,Aspartate,Aspartate Magnesium Hydrochloride,Aspartic Acid, Ammonium Salt,Aspartic Acid, Calcium Salt,Aspartic Acid, Dipotassium Salt,Aspartic Acid, Disodium Salt,Aspartic Acid, Hydrobromide,Aspartic Acid, Hydrochloride,Aspartic Acid, Magnesium (1:1) Salt, Hydrochloride, Trihydrate,Aspartic Acid, Magnesium (2:1) Salt,Aspartic Acid, Magnesium-Potassium (2:1:2) Salt,Aspartic Acid, Monopotassium Salt,Aspartic Acid, Monosodium Salt,Aspartic Acid, Potassium Salt,Aspartic Acid, Sodium Salt,Calcium Aspartate,Dipotassium Aspartate,Disodium Aspartate,L-Aspartate,L-Aspartic Acid,Magnesiocard,Magnesium Aspartate,Mg-5-Longoral,Monopotassium Aspartate,Monosodium Aspartate,Potassium Aspartate,Sodium Aspartate,Aspartate, Ammonium,Aspartate, Calcium,Aspartate, Dipotassium,Aspartate, Disodium,Aspartate, Magnesium,Aspartate, Monopotassium,Aspartate, Monosodium,Aspartate, Potassium,Aspartate, Sodium,L Aspartate,L Aspartic Acid

Related Publications

J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.
April 1992, Seminars in oncology,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
N-(Phosphonacetyl)-L-aspartate (PALA): current status.
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Phase I trial of N-(phosphonacetyl)-L-aspartate.
October 1979, Cancer research,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
January 1984, Journal of the American Academy of Dermatology,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Response of psoriasis to N-phosphonacetyl-L-aspartate.
June 1981, Lancet (London, England),
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
July 1992, Annals of internal medicine,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
January 1980, Cancer research,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
November 1974, The Journal of biological chemistry,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
January 1982, Molecular pharmacology,
J L Grem, and S A King, and P J O'Dwyer, and B Leyland-Jones
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
August 1976, Cancer research,
Copied contents to your clipboard!